Targets › LDHA
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Genitourinary; next expected readout Apr 2030.
Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+). Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to L-2-hydroxyglutarate. (UniProt, P00338)
Open in Phaseline: the race on LDHA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Nedosiran Sodium L-lactate dehydrogenase A chain mRNA RNAi inhibitor | LDHA | Phase 3 | Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 1 | Apr 2030 |
Primary Hyperoxaluria Type 1 (PH1) (1) Primary Hyperoxaluria Type 1 (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.